PHOENIXVILLE, PA — PleoPharma, Inc. has announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to PP-01, the company’s lead investigational asset aimed at ...

Forbes contributors publish independent expert analyses and insights. Dario Sabaghi covers the cannabis industry with a focus on Europe. Pharmaceutical development company PleoPharma has received a ...

Heavy users of cannabis who experience withdrawal symptoms such as nervousness and cravings when they quit are likely to use again sooner than their peers, a new study finds. Researchers at the ...

January 31, 2008 — Cannabis withdrawal is clinically important and warrants inclusion in the Diagnostic and Statistical Manual ( DSM), researchers argue in an article in the January 1 issue of Drug ...

PHOENIXVILLE, PA — PleoPharma, Inc. has closed a $36 million Series B financing round to accelerate development of PP-01, its lead investigational therapy for Cannabis Withdrawal in patients with ...

NEW YORK--(BUSINESS WIRE)--Pelago, the leading digital clinic partner to U.S. businesses and health plans for substance use management, has announced the addition of cannabis to its specialized ...

Marijuana helps people with substance misuse disorders stay off opioids or reduce their use, maintain treatment, and manage withdrawal symptoms, a new federally funded study finds. Researchers at the ...

Cannabis use disorder (CUD), also known as marijuana use disorder, is defined by compulsive use of cannabis despite adverse consequences, difficulty controlling use, and withdrawal symptoms. The ...

Findings from a phase 2b study showed participants treated with PP-01 had a statistically significant reduction in cannabis withdrawal symptoms compared with placebo. The Food and Drug Administration ...